Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 803 across all filing types
Latest filing 2026-06-08 Capital/Financing Update
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Reminder: Nicox June 2024 Warrants will expire June 19, 2026
Capital/Financing Update Classification · 80% confidence The document is a corporate press release reminding holders of Nicox’s June 2024 warrants of their upcoming expiration and delisting. It provides details on the warrant terms (exercise period, price, parity) and explains the procedural steps for exercise. This is not an earnings release, not a financial report, and not a regulatory filing about dividends or management changes. Rather, it concerns a change to the company’s capital structure (the expiry and removal of a financing instrument). This fits the definition of a Capital/Financing Update (CAP).
2026-06-08 English
Rappel : les BSA Nicox de juin 2024 expireront le 19 juin 2026
Capital/Financing Update Classification · 85% confidence The document is a press release (“Communiqué de presse”) reminding holders of warrants (BSA) issued in June 2024 about their expiration date, trading details, exercise terms, and procedures. It concerns the company’s capital structure and instruments rather than a formal report or regulatory filing. This falls under ‘Capital/Financing Update’ (CAP), as it provides information on a financing instrument and its terms.
2026-06-08 French
Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 24 juin 2026 et désignation d’un mandataire ad hoc
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a convocation notice (“convocation à l’Assemblée Générale Ordinaire et Extraordinaire”) informing shareholders of the date, agenda, text of resolutions, proxy arrangements, voting modalities, and where to access meeting materials. This type of shareholder meeting notice and voting information falls under Proxy Solicitation & Information Statement (PSI).
2026-06-03 French
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative
Proxy Solicitation & Information Statement Classification · 82% confidence The document is a press release notifying shareholders of the Ordinary and Extraordinary General Meeting date, agenda, draft resolutions and details on how to participate and vote (by proxy, internet or in person), including the appointment of an ad hoc representative to ensure quorum. It is effectively the notice of meeting and provision of proxy information, matching the definition of a Proxy Solicitation & Information Statement rather than a full annual report or regulatory filing.
2026-06-03 English
Nicox annonce ses résultats financiers 2025 et fait un point sur son activité
Annual Report Classification · 95% confidence The document is a detailed financial announcement titled "Nicox annonce ses résultats financiers 2025 et fait un point sur son activité" which translates to "Nicox announces its 2025 financial results and provides an update on its activity." It includes comprehensive financial data such as income statement, balance sheet, and detailed commentary on revenues, losses, and strategic outlook. The document references the fiscal year 2025 and contains actual financial statements and analysis. It is not a brief announcement or a notice of report publication but a full financial report for the year. Therefore, it fits the definition of an Annual Report (10-K equivalent). FY 2025
2026-04-30 French
Nicox Provides Full Year 2025 Financial Results and Corporate Update
Annual Report Classification · 95% confidence The document is a press release dated April 30, 2026, providing full year 2025 financial results and a corporate update for Nicox SA. It includes detailed financial data such as revenue, net loss, operating expenses, income statement, and balance sheet figures for the full fiscal year 2025. The document also discusses future milestones, regulatory updates, and strategic plans. The presence of comprehensive financial statements and analysis for the full fiscal year indicates this is a full annual financial report rather than a brief earnings release or announcement. The document length (11,641 characters) and detailed financial tables confirm it is not a short announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K) type filing, as it covers the company's full year financial performance and activities. FY 2025
2026-04-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.